Surprising connection sits at the center of this dementia and brain health question.

Yes, there is evidence of a connection between long-term heartburn medication use and increased dementia risk—but the relationship is far more complex and less conclusive than headlines often suggest. A large Danish study tracking nearly 2 million people over 18 years found that individuals on proton pump inhibitors (PPIs) like omeprazole had a 36% higher dementia risk when diagnosed in their 60s, though this risk declined significantly in older age groups. However, this same body of research is deeply contradictory: other major studies found no connection at all, and medical organizations like the American College of Gastroenterology have pushed back against what they call “sensational claims” about PPI safety. This article explores what the research actually shows, why experts disagree, and what it means for the millions of people taking these drugs daily for heartburn and acid reflux.

What Do Large Population Studies Reveal About PPIs and Dementia Risk?
Why Do Some Studies Show a Link While Others Find Nothing?
Age Matters More Than You Might Think
Does the Length and Amount of PPI Use Change the Risk?
What Does the Medical Establishment Actually Recommend?
Long-Term PPI Use and Vitamin B12 Deficiency
What Should Change If You’re Currently Taking PPIs for Heartburn?
Conclusion

What Do Large Population Studies Reveal About PPIs and Dementia Risk?

The most striking evidence comes from a Danish nationwide study published in a peer-reviewed journal, which followed 1,983,785 individuals aged 60-75 over 18 years and identified 99,384 dementia cases. The researchers found that people who had ever used PPIs showed a 36% increased dementia risk (incidence rate ratio of 1.36) compared to never-users—but only among those diagnosed at ages 60-69. The picture changes dramatically with age: the excess risk dropped to 12% for those diagnosed at ages 70-79, then to 6% for ages 80-89, and just 3% for those 90 and older. This age-related pattern is crucial because it suggests either a selection effect (people with early-onset dementia may take more medication) or that PPI use primarily affects younger brains differently than older ones.

A separate 2025 meta-analysis examining dozens of published studies found highly inconsistent results depending on geography and study design. Observational studies conducted in Asian populations reported increased dementia risk, while Western-based studies showed inconsistent findings—some suggesting a link, others showing none. This variability is a red flag in medical research: when populations and methods vary widely, it often means the true effect is either very small, doesn’t exist, or is heavily influenced by factors researchers can’t fully control. For example, people who take PPIs might also differ in other ways (diet, exercise, medication use) that could independently affect dementia risk, making it difficult to isolate PPI use as the culprit.

What Do Large Population Studies Reveal About PPIs and Dementia Risk?

Why Do Some Studies Show a Link While Others Find Nothing?

When researchers analyzed the actual biological mechanisms that might connect PPIs to dementia, they identified several plausible pathways: PPIs may inhibit vacuolar ATPase proteins in the brain, which could disrupt how brain cells clean up damaged proteins; they may alter how immune cells called microglia handle amyloid-beta (a hallmark of Alzheimer’s disease); and they may trigger synaptic dysfunction. These mechanisms sound convincing in laboratory settings, but proving they cause dementia in living people is another matter entirely. The most rigorous type of evidence—prospective cohort studies following healthy older adults over time—has painted a different picture: one major prospective study of adults aged 65 and older found absolutely no association between PPI use and incident dementia, cognitive impairment, or declining cognitive function scores, even with years of follow-up.

A genetic analysis (Mendelian randomization study) provided no strong genetic evidence that specific PPIs cause dementia risk across different dementia subtypes, which would be expected if the connection were truly causal. The key limitation here is distinguishing correlation from causation: observational studies might show that PPI users develop dementia more often, but that could mean dementia causes acid reflux (people with early cognitive decline might have trouble swallowing or managing medication), rather than the other way around. This reverse causality is especially relevant for dementia, where early symptoms can be subtle and undiagnosed for years.

Age Matters More Than You Might Think

The Danish study’s most revealing finding was buried in the age-stratified data: dementia risk from PPI use decreased dramatically across successive age groups. For someone diagnosed at age 62, the 36% excess risk is substantial and worth considering. But jump to age 75, and you’re looking at only a 12% increase. By age 85, the connection has shrunk to 6%, and by 90, it’s down to just 3%. This pattern has two possible explanations.

First, it might reflect “survival bias”—people who developed dementia from PPIs in their 60s are already counted in the study, so by the time you reach age 90, you’re comparing only the healthiest PPI users (those who didn’t develop early dementia) against never-users who are also healthier than average. Second, it might suggest that younger brains are more vulnerable to whatever effect PPIs have, while older brains are either naturally more resilient or less likely to be affected. For a 70-year-old taking an antacid, the practical implication is significant: the absolute risk increase is much smaller than headlines about the Danish study might suggest. If the baseline dementia risk for a never-user at age 70 is around 1-2% over the next five years, a 12% relative increase brings it to roughly 1.1-2.2%—a modest change. But for someone in their early 60s who might take PPIs for decades, the stakes are higher, which is why duration of use matters.

Does the Length and Amount of PPI Use Change the Risk?

One of the clearest findings across multiple studies is the concept of a cumulative dose threshold: individuals who used PPIs for more than 4 years accumulated a 33% greater dementia risk compared to never-users, but people who took the medications for 4.4 years or less showed no increased connection to dementia. This suggests there’s a critical window—somewhere between 4 and 4.4 years—where a shift in risk might occur. However, this finding doesn’t necessarily mean the risk climbs gradually; it could mean there’s a sharp threshold effect where brief use is safe, but sustained use crosses into riskier territory.

The practical challenge is that many people take PPIs not for a discrete 4-year stretch but for decades. Someone diagnosed with severe reflux at age 50 might remain on omeprazole or another PPI until age 85 or beyond. In such cases, the cumulative exposure far exceeds the threshold associated with increased risk in the Danish study. Yet the question remains unanswered in current research: does 20 years of PPI use represent a proportionally higher risk than 4 years, or does the risk plateau after hitting that threshold? The lack of clarity here is frustrating for patients and doctors trying to make informed decisions.

What Does the Medical Establishment Actually Recommend?

In October 2023, the American College of Gastroenterology published a position paper with the blunt title: “PPIs are NOT Associated with Dementia: Refuting Sensational Claims in a Post-Modern Epidemiologic Era.” The organization essentially took sides against the Danish study’s headlines, arguing that observational studies cannot establish causation and that the most rigorous evidence (prospective cohort studies) shows no link. Their position reflects a deep skepticism of how media outlets and even some researchers have portrayed PPI safety. From the ACG’s perspective, the methodological weaknesses in the studies suggesting PPI-dementia links are severe enough to outweigh the findings entirely. However, dismissing the Danish study outright isn’t appropriate either.

It was a massive, well-designed study in a national health system with reliable diagnostic data. The fact that it found an age-specific pattern rather than a uniform risk suggests genuine biological effects rather than random noise. The ongoing scientific disagreement reflects the genuine difficulty of studying medication effects on brain health in aging populations—a problem that won’t resolve quickly. For now, the honest answer is that evidence is mixed, which means individual decisions should account for personal circumstances rather than relying on any single study or position paper.

What Does the Medical Establishment Actually Recommend?

Long-Term PPI Use and Vitamin B12 Deficiency

One biological pathway with stronger consensus support is the vitamin B12 mechanism. Long-term PPI use is well-established to reduce stomach acid, and stomach acid is necessary to absorb B12 from food. Multiple studies confirm that people on PPIs have lower B12 levels, and B12 deficiency is a known risk factor for cognitive decline and neurological damage. Unlike the proposed mechanisms involving brain inflammation or protein handling, the B12 pathway has a clear chain: less stomach acid → lower B12 absorption → depleted B12 stores → neurological consequences.

This might be one genuinely important mechanism linking PPI use to dementia risk, independent of the speculative pathways about brain inflammation. For patients, this suggests a practical monitoring point: anyone on long-term PPIs should have their B12 levels checked periodically (annual testing is reasonable) and consider supplementation if levels are low. B12 supplementation can be given as oral supplements, nasal sprays, or injections, all of which bypass the stomach acid requirement. This is something within the control of patients and doctors, unlike the more speculative claims about direct brain effects. The B12 pathway also offers a potential mechanism for harm that could be mitigated without stopping the PPI—something the broader dementia-risk debate sometimes overlooks.

What Should Change If You’re Currently Taking PPIs for Heartburn?

If you’re taking a PPI and reading about dementia risk, the instinct to stop immediately is understandable but potentially unwise. Sudden discontinuation of PPIs can cause severe rebound acid reflux lasting weeks or months, which is both miserable and potentially damaging to the esophagus. For many people with severe reflux, GERD, or ulcers, the immediate benefit of PPI therapy (healing ulcers, reducing inflammation, improving quality of life) far outweighs the uncertain, age-dependent dementia risk suggested by one large study. The risk-benefit calculation differs dramatically for someone in their 90s with mild reflux (risk-benefit favors discontinuation) versus a 55-year-old with Barrett’s esophagus or recurring ulcers (risk-benefit still likely favors continuing).

What’s more actionable is a conversation with your doctor about deprescribing—reducing the dose or frequency of PPIs if possible, rather than stopping abruptly. Some patients can manage reflux with intermittent PPI use (taking a pill only when needed) rather than daily maintenance therapy, which reduces cumulative exposure. For new PPI prescriptions, the trend among experts is toward the shortest effective duration: using PPIs to heal an ulcer for 8 weeks, then stopping, rather than prescribing indefinitely. And as mentioned, monitoring B12 levels and supplementing if necessary is a concrete step to address one known risk pathway.

Conclusion

The connection between heartburn medication and dementia risk is real enough to warrant attention but not certain enough to overturn current treatment guidelines. The evidence is contradictory: a large Danish study suggests PPIs may increase dementia risk in younger users, particularly with more than 4 years of cumulative use, while equally rigorous prospective studies and genetic analyses find no causal link. What seems most likely from current evidence is that any effect is modest, age-dependent, and concentrated in younger populations rather than affecting older adults significantly. The medical community remains divided, with gastroenterologists skeptical of PPI-dementia claims while neuroscientists continue investigating proposed biological mechanisms.

If you’re currently taking PPIs, this research doesn’t justify panic or sudden changes to your medication. Instead, use it as a prompt for a strategic conversation with your doctor about whether you truly need long-term daily therapy or whether lower doses, intermittent use, or an eventual deprescribing plan might work for your specific situation. For new diagnoses of reflux, ask about the shortest effective treatment duration rather than defaulting to indefinite use. And for anyone on long-term PPIs, routine B12 monitoring is a concrete, evidence-based step toward protecting your brain health. The research frontier on this topic is still wide open—stronger evidence may emerge in coming years—but current data doesn’t support abandoning these medications, which remain highly effective for treating serious acid reflux and preventing ulcers.